643 A first in human phase I/IIa trial of personalized tumor-trained lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer

• Maximilian Kordes,
• Sofia Berglund,
• Ola Nilsson,
• Jeffrey Yachnin,
• Maziar Nikberg,
• Abbas Chabok,
• Erwan Le Maître,
• Anne-Laure Joly,
• Luigi Notari,
• Guro Gafvelin,
• Hans Grönlund,
• Kelly Day,
• Claudia Carvalho-Queiroz,
• Andreas Kaiser,
• Mattias Carlsten,
• Stephan Mielke,
• Ahmed Salim Tarfy,
• Andrea Salmén,
• Samuel Svensson,
• Hanjing Xie

Affiliations

Maximilian Kordes

Tema Cancer, Karolinska University Hospital, Stockholm, Sweden

Sofia Berglund

Aff276 grid.21107.350000000121719311Johns Hopkins University Baltimore MD USA

Ola Nilsson

Center for Molecular Medicine and Pediatric Endocrinology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

Jeffrey Yachnin

1Karolinska Institutet, Stockholm, Sweden

Maziar Nikberg

5Centre for Clinical Research of Uppsala University, Västmanlands hospital Västerås, Västerås, Sweden

Abbas Chabok

5Centre for Clinical Research of Uppsala University, Västmanlands hospital Västerås, Västerås, Sweden

Erwan Le Maître

Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden

Anne-Laure Joly

2Neogap Therapeutics AB, Stockholm, Sweden

Luigi Notari

Karolinska Institutet, Stockholm, Sweden

Guro Gafvelin

Karolinska Institutet, Stockholm, Sweden

Hans Grönlund

Karolinska Institutet, Stockholm, Sweden

Kelly Day

2Neogap Therapeutics AB, Stockholm, Sweden

Claudia Carvalho-Queiroz

2Neogap Therapeutics AB, Stockholm, Sweden

Andreas Kaiser

1Karolinska Institutet, Stockholm, Sweden

Mattias Carlsten

1Karolinska Institutet, Stockholm, Sweden

Stephan Mielke

1Karolinska Institutet, Stockholm, Sweden

Ahmed Salim Tarfy

5Centre for Clinical Research of Uppsala University, Västmanlands hospital Västerås, Västerås, Sweden

Andrea Salmén

2Neogap Therapeutics AB, Stockholm, Sweden

Samuel Svensson

2Neogap Therapeutics AB, Stockholm, Sweden

Hanjing Xie

1Karolinska Institutet, Stockholm, Sweden